- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01481636
Assessing the Symptoms of Obstructive Sleep Apnea (OSA)
16 de junho de 2014 atualizado por: Bangor University
Association of Health Outcomes With Severity of OSA Symptomatology- a Correlation Study.
The purpose of this study is to investigate the correlation between health outcomes associated with the severity of obstructive sleep apnea (OSA) symptomatology, the findings will guide the design of interventional studies.
Visão geral do estudo
Status
Concluído
Condições
Descrição detalhada
Obstructive sleep apnea is a condition characterised by periods of narrowing of the pharyngeal airways during sleep causing hypoxic and hypercapnic episodes with the cessation of ventilation.
Considering the high number of overweight and obese individuals in Western society the understanding of the pathomechanisms behind OSA are important.
This observational study aims to investigate the correlations between the severity of Obstructive Sleep Apnea assessed by the apnea-hypopnea index (AHI) and different health outcomes associated with the OSA.
Tipo de estudo
Observacional
Inscrição (Real)
66
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Gwynedd
-
Bangor, Gwynedd, Reino Unido, LL57 2PW
- Betsi Cadwaladr University Health Board
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 70 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Macho
Método de amostragem
Amostra Não Probabilística
População do estudo
Mild to severe recently diagnosed Obstructive Sleep Apnea patients selected by physician who have not received any treatment for their condition.
Selected from Ysbyty Gwynedd in North Wales.
Descrição
Inclusion Criteria:
- Body Mass Index ≤39
- Not received any treatment for Obstructive Sleep Apnea.
- Is a non-smoker
- Is not epileptic
- Epworth Sleepiness Scale ≥ 10.
- Patient's on Statins or antihypertensive drugs are included as so frequent in OSA.
Exclusion Criteria:
- Body Mass Index ≥ 39.
- Presence of significant or unstable Renal, Liver or Heart Failure.
- Receiving anti-diabetic treatment.
- Is a smoker.
- Is epileptic
- Presence of significant or unstable psychological morbidities.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
---|
No treatment, OSA (AHI >15)
Patients with OSA recruited prior to receiving NHS treatment.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Apnea-Hypopnea Index (AHI)
Prazo: one night within four weeks of study.
|
AHI refers to how is the number of apneas and hypopneas per an hour of sleep.
|
one night within four weeks of study.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Residual volume
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Volume of air remaining in lungs after full expiration
|
Within four weeks of recruitment prior to CPAP treatment
|
Functional residual volume
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Air present in lungs at the end of passive expiration
|
Within four weeks of recruitment prior to CPAP treatment
|
Total lung capacity
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Total volume of lungs
|
Within four weeks of recruitment prior to CPAP treatment
|
Forced Vital capacity
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Maximum amount of air which can be expired from the lungs following a full inspiration
|
Within four weeks of recruitment prior to CPAP treatment
|
Forced expiratory volume in one second (FEV1)
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Maximum amount of air which can be expired from the lungs in one second.
|
Within four weeks of recruitment prior to CPAP treatment
|
Airway Resistance
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Opposition of flow caused by forces of friction.
|
Within four weeks of recruitment prior to CPAP treatment
|
Plasma 2-arachidonoylglycerol (2-AG)
Prazo: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment.
|
Ligand of the G-protein coupled CB1 and CB2 receptors, has been found to be correlated with Oleylethanolamide (OEA) in OSA patients have various effects on energy metabolism.
|
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment.
|
Plasma Anandamide (ANA)
Prazo: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Ligand of the G-protein coupled CB1 and CB2 receptors, found to be correlated with blood pressure in OSA after the adjustment of confounding variables.
Have various effects on energy metabolism.
|
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Plasma oleoylethanolamine (OEA)
Prazo: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
A lipid mediator which acts as an anorexigenic (appetite suppressant), and is elevated with sleep deprivation.
|
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Plasma Leptin
Prazo: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Circulating protein produced in adipose tissue.
Elevated in OSA and obesity.
Leptin may reduce respiratory depression.
|
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Plasma Adiponectin
Prazo: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Hormone secreted by adipocytes (Fat cells).
Adiponectin is closely linked to metabolism and may have anti-inflammatory properties.
|
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Plasma C-reactive Protein
Prazo: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Marker of inflammation.
|
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Insulin
Prazo: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Hormone which causes liver and muscle and fat cells to take up glucose to convert to glycogen.
OSA is associated with insulin resistance.
|
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
|
Neck circumference
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Within four weeks of recruitment prior to CPAP treatment
|
|
Waist circumference
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Within four weeks of recruitment prior to CPAP treatment
|
|
Hip circumference
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Within four weeks of recruitment prior to CPAP treatment
|
|
Weight
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Within four weeks of recruitment prior to CPAP treatment
|
|
Fat-free mass
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Non-fat components of the human body estimated non-invasively using a bioimpedance measurement system.
|
Within four weeks of recruitment prior to CPAP treatment
|
Fat mass
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Fat components of the human body estimated non-invasively using bioimpedance measurement system.
|
Within four weeks of recruitment prior to CPAP treatment
|
Maximal Inspiratory pressure
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Measured at residual volume, reflects the strength of the diaphragm and other inspiratory muscles.
|
Within four weeks of recruitment prior to CPAP treatment
|
Rate of inspiratory muscle fatigue
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
The decline in maximal inspiratory pressure following inspiration against a resistance.
|
Within four weeks of recruitment prior to CPAP treatment
|
Chest RPE
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Rating of perceived exertion in the chest and associated airways during the inspiratory fatigue protocol.
|
Within four weeks of recruitment prior to CPAP treatment
|
Dyspnea
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Rating of breathlessness half way through fatigue protocol and at the end of protocol.
|
Within four weeks of recruitment prior to CPAP treatment
|
Ventilation with 25% O2/ 6% CO2
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Measures the breathing response to high oxygen and high CO2 therefore assessing the central chemoreceptors response only.
|
Within four weeks of recruitment prior to CPAP treatment
|
Ventilation with 13% O2
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Measures the breathing response to low oxygen.
Designed to Assess the response to the peripheral chemoreceptors.
|
Within four weeks of recruitment prior to CPAP treatment
|
Ventilation with 13% O2 / 6% CO2
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Measures the breathing response to low oxygen and high CO2.
Designed to assess the response of the sum of the peripheral and central chemoreceptors
|
Within four weeks of recruitment prior to CPAP treatment
|
Mean RR interval
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Time domain measure: Average time interval between the heart beats R waves
|
Within four weeks of recruitment prior to CPAP treatment
|
SDNN
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Time domain measure: The standard deviation of all RR intervals
|
Within four weeks of recruitment prior to CPAP treatment
|
NN50 count
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Time domain measure: The number of pairs of adjacent RR intervals differing by more than 50 ms in the entire analysis interval.
|
Within four weeks of recruitment prior to CPAP treatment
|
NN50 of total HR (%)
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
Time domain measure: NN50 count divided by total number of all RR intervals.
|
Within four weeks of recruitment prior to CPAP treatment
|
HRV triangular index
Prazo: Within four weeks of recruitment prior to CPAP treatment
|
The total number of RR intervals divided by maximum height of the histogram excluding boundaries.
|
Within four weeks of recruitment prior to CPAP treatment
|
Low frequency domain
Prazo: Within four weeks of recruitment prior to CPAP treatment.
|
Frequency domain analysis: represents 0.04-0.15
Hz reflecting sympathetic activity.
|
Within four weeks of recruitment prior to CPAP treatment.
|
High frequency domain
Prazo: Within four weeks of recruitment prior to CPAP treatment.
|
Frequency domain analysis: represents 0.15-0.40
Hz reflecting parasympathetic activity.
|
Within four weeks of recruitment prior to CPAP treatment.
|
LF/HF ratio
Prazo: Within four weeks of recruitment prior to CPAP treatment.
|
The ratio of low frequency (0.04 - 0.15 Hz) to high (0.15-0.40 Hz) frequency recordings.
|
Within four weeks of recruitment prior to CPAP treatment.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Christopher MN Earing, MSc, School of Sport, Health and Exercise Sciences, Bangor University
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de novembro de 2011
Conclusão Primária (Real)
1 de junho de 2014
Conclusão do estudo (Real)
1 de junho de 2014
Datas de inscrição no estudo
Enviado pela primeira vez
24 de novembro de 2011
Enviado pela primeira vez que atendeu aos critérios de CQ
24 de novembro de 2011
Primeira postagem (Estimativa)
29 de novembro de 2011
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
17 de junho de 2014
Última atualização enviada que atendeu aos critérios de controle de qualidade
16 de junho de 2014
Última verificação
1 de junho de 2014
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- REC No: 11/WNo:01/2
- Earing 11/WNo01/2 (Outro identificador: North West Wales Research Ethics Committee)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .